Trials / Recruiting
RecruitingNCT07426380
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
A Phase 1, Multicenter, Parallel-Design, Single Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Eloralintide in Participants With Severe Renal Impairment and End Stage Renal Disease (ESRD) Compared With Participants With Normal Renal Function
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to assess the amount of Eloralintide (LY3841136) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants. The study drug will be administered subcutaneously (SC) (under the skin). For each participant, the study will last about 14 weeks, excluding screening.
Conditions
- Kidney Disease
- Renal Insufficiency Chronic
- Kidney Failure, Chronic
- Renal Impairment
- Renal Insufficiency
- End Stage Kidney Disease
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3841136 | Administered SC |
Timeline
- Start date
- 2026-02-24
- Primary completion
- 2026-10-01
- Completion
- 2026-10-01
- First posted
- 2026-02-23
- Last updated
- 2026-03-13
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07426380. Inclusion in this directory is not an endorsement.